Optimization of a Mucoadhesive Vaginal Gel Containing Clotrimazole Using a D-Optimal Experimental Design and Multivariate Analysis.
FT-IR
bioadhesion
multivariate analysis
polyacrylic acid
polyethene oxides
statistical optimization
vaginal candidiasis
Journal
Polymers
ISSN: 2073-4360
Titre abrégé: Polymers (Basel)
Pays: Switzerland
ID NLM: 101545357
Informations de publication
Date de publication:
24 Apr 2023
24 Apr 2023
Historique:
received:
31
03
2023
revised:
19
04
2023
accepted:
23
04
2023
medline:
13
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
The aim of this study was to develop a suitable clotrimazole (CLT)-loaded mucoadhesive vaginal gel (CLT-MVG) for topical applications in vaginal candidiasis. Ten CLT-MVG formulations were prepared, consisting of mixtures of acid polyacrylic (Carbopol 940) and polyethene oxides, Sentry Polyox WSRN 1105 or 750, according to an experimental D-optimal design, and CLT was suspended at a ratio of 1%. The prepared CLT-MVG formulations were studied in vitro, and the formulation containing Carbopol 940 0.89% combined with PEO 1105 1.39% was identified with the optimal rheological and in vitro bioadhesion properties, ensuring the prolonged release of CLT, with a similarity factor greater than 50, indicating dissolution profile similarity for three batches of the optimized formulation. This optimized formulation showed a pH in the tolerance range, and an adequate ex vivo mucoadhesion time, while the FT-IR studies revealed no interactions between the excipients and CLT. The microscopic analysis identified a mean particle size of suspended CLT of 5.24 ± 0.57 μm. The in vitro antifungal activity of the optimized formulation was tested on twenty strains of
Identifiants
pubmed: 37177171
pii: polym15092023
doi: 10.3390/polym15092023
pmc: PMC10181139
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Curr Pharm Des. 2015;21(29):4285-309
pubmed: 26323422
Polymers (Basel). 2022 Nov 26;14(23):
pubmed: 36501540
Pharm Dev Technol. 2020 Dec;25(10):1238-1248
pubmed: 32787718
Pharm Dev Technol. 2017 Jun;22(4):551-561
pubmed: 27055376
Am J Obstet Gynecol. 2016 Jan;214(1):15-21
pubmed: 26164695
Mater Sci Eng C Mater Biol Appl. 2017 Oct 1;79:886-893
pubmed: 28629093
Folia Med (Plovdiv). 2019 Jun 1;61(2):266-276
pubmed: 31301667
Pharmaceutics. 2021 Oct 15;13(10):
pubmed: 34683995
Curr Mol Pharmacol. 2021;14(3):281-291
pubmed: 32564767
Curr Infect Dis Rep. 2019 Nov 9;21(11):44
pubmed: 31707496
Int J Pharm. 2021 Nov 20;609:121182
pubmed: 34648879
Curr Infect Dis Rep. 2015 Jun;17(6):462
pubmed: 25916994
Adv Drug Deliv Rev. 2015 Sep 15;92:105-22
pubmed: 26144995
Eur J Pharm Biopharm. 2015 Oct;96:173-84
pubmed: 26235393
Menopause. 2016 Apr;23(4):368-75
pubmed: 26645820
Drug Deliv. 2021 Dec;28(1):814-825
pubmed: 33899634
Saudi Pharm J. 2019 Dec;27(8):1096-1106
pubmed: 31885469
Drug Deliv. 2016;23(2):550-63
pubmed: 24959937
Gels. 2021 Dec 12;7(4):
pubmed: 34940319
Int J Pharm Investig. 2016 Jan-Mar;6(1):47-55
pubmed: 27014619
Clin Infect Dis. 2019 May 17;68(11):1791-1797
pubmed: 30204844
ScientificWorldJournal. 2014 Mar 24;2014:280928
pubmed: 24790559
Curr Drug Deliv. 2009 Jan;6(1):83-92
pubmed: 19418960
Lancet Infect Dis. 2018 Nov;18(11):e339-e347
pubmed: 30078662
Pharmaceutics. 2021 Jun 15;13(6):
pubmed: 34203714
Eur J Pharm Sci. 2018 Jan 1;111:358-375
pubmed: 28986195
Molecules. 2019 Jul 12;24(14):
pubmed: 31336916
Molecules. 2020 Mar 27;25(7):
pubmed: 32230990
Pharmaceutics. 2023 Feb 08;15(2):
pubmed: 36839899